Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. SciClone Pharmaceuticals (Holdings) Limited
  6. Summary
    6600   KYG4271B1023

SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

(6600)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
11/30/2021 12/01/2021 12/02/2021 12/03/2021 12/06/2021 Date
9.07 8.9 8.65 8.35 8.7 Last
144500 255500 528000 378000 678402 Volume
-1.09% -1.87% -2.81% -3.47% +4.19% Change
Estimated financial data (e)
Sales 2021 2 439 M 383 M 383 M
Net income 2021 890 M 140 M 140 M
Net cash position 2021 719 M 113 M 113 M
P/E ratio 2021 5,37x
Yield 2021 5,39%
Sales 2022 2 700 M 424 M 424 M
Net income 2022 950 M 149 M 149 M
Net cash position 2022 1 482 M 233 M 233 M
P/E ratio 2022 5,08x
Yield 2022 -
Capitalization 4 798 M 753 M 753 M
EV / Sales 2021 1,67x
EV / Sales 2022 1,23x
Nbr of Employees 850
Free-Float 56,2%
More Financials
Company
SciClone Pharmaceuticals Holdings Ltd is a China-based biopharmaceutical company principally engaged in developing and commercializing a portfolio of marketed products as well as pipeline with potential in its focused therapeutic areas including oncology and severe infection. The Company primarily engages in the sales of its proprietary product, Zadaxin, its in-licensed products and promotion products on behalf of... 
Sector
Pharmaceuticals
Calendar
-
More about the company
All news about SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
11/09SciClone Pharmaceuticals Grants Nearly 4 Million Share Options
MT
09/20SCICLONE PHARMACEUTICALS LIMITED(SEH : 6600) added to S&P Global BMI Index
CI
09/15SCICLONE PHARMACEUTICALS : Wins License for Preclinical Miniature Solid Tumor Inhibitor
MT
09/14Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA (naxitamab-gqgk) in..
AQ
09/13SCICLONE PHARMACEUTICALS : Gets Priority Review for Neuroblastoma Treatment in China
MT
09/10NMPA Grants Priority Review to BLA of DANYELZA®
CI
09/03610,329,800 Ordinary Shares of SciClone Pharmaceuticals Limited are subject to a Lock-U..
CI
08/19Sciclone Pharmaceuticals Limited Announces Unaudited Consolidated Financial Results for..
CI
08/10ThinkGeek Network Technology Files for Hong Kong IPO
MT
08/05Beijing Evercare Medical Files for Hong Kong IPO
MT
07/13SCICLONE PHARMACEUTICALS : China Accepts SciClone Pharma's Biologics License Application f..
MT
07/12SciClone Pharmaceuticals Announces NMPA Acceptance of BLA of DANYELZA (naxitamab-gqgk)
CI
07/07Y MABS THERAPEUTICS : mAbs Announces NMPA Submission of BLA for DANELZA (naxitamab-gqgk) i..
AQ
07/06SciClone Pharmaceuticals Limited submits the Biologics License Application for DANYELZA..
CI
06/22MARKET CHATTER : Medlive Technology Passes Hong Kong Listing Hearing
MT
More news
News in other languages on SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
07/13La Chine accepte la demande de licence de produits biologiques de SciClone Pharma pour ..
More news
Chart SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Duration : Period :
SciClone Pharmaceuticals (Holdings) Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 7,11 CNY
Average target price 14,94 CNY
Spread / Average Target 110%
EPS Revisions
Managers and Directors
Hong Zhao President, CEO & Executive Director
Zhen Fu Li Chairman
Ping Chen Independent Non-Executive Director
Wendy Hayes Independent Non-Executive Director
Guo En Liu Independent Non-Executive Director
Sector and Competitors